MX2024009338A - Composiciones y metodos para tratamiento de canceres positivos a mesotelina. - Google Patents

Composiciones y metodos para tratamiento de canceres positivos a mesotelina.

Info

Publication number
MX2024009338A
MX2024009338A MX2024009338A MX2024009338A MX2024009338A MX 2024009338 A MX2024009338 A MX 2024009338A MX 2024009338 A MX2024009338 A MX 2024009338A MX 2024009338 A MX2024009338 A MX 2024009338A MX 2024009338 A MX2024009338 A MX 2024009338A
Authority
MX
Mexico
Prior art keywords
methods
compositions
positive cancers
mesothelin positive
treating
Prior art date
Application number
MX2024009338A
Other languages
English (en)
Spanish (es)
Inventor
Carl Alexander Kamb
Dora Toledo Warshaviak
Talar Tokatlian
Agnes E Hamburger
Grace E Asuelime
Original Assignee
A2 Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A2 Biotherapeutics Inc filed Critical A2 Biotherapeutics Inc
Publication of MX2024009338A publication Critical patent/MX2024009338A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2024009338A 2022-01-28 2023-01-27 Composiciones y metodos para tratamiento de canceres positivos a mesotelina. MX2024009338A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263304409P 2022-01-28 2022-01-28
PCT/US2023/011698 WO2023147019A2 (en) 2022-01-28 2023-01-27 Compositions and methods for treating mesothelin positive cancers

Publications (1)

Publication Number Publication Date
MX2024009338A true MX2024009338A (es) 2024-08-09

Family

ID=87472570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009338A MX2024009338A (es) 2022-01-28 2023-01-27 Composiciones y metodos para tratamiento de canceres positivos a mesotelina.

Country Status (10)

Country Link
US (1) US20250269027A1 (https=)
EP (1) EP4469559A4 (https=)
JP (1) JP2025503967A (https=)
KR (1) KR20240155391A (https=)
CN (1) CN119403921A (https=)
AU (1) AU2023213691A1 (https=)
CA (1) CA3243381A1 (https=)
IL (1) IL314114A (https=)
MX (1) MX2024009338A (https=)
WO (1) WO2023147019A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025030141A1 (en) * 2023-08-02 2025-02-06 A2 Biotherapeutics, Inc. Compositions and methods for treating cancers with hla-a*03 loss of expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109504696A (zh) * 2017-09-15 2019-03-22 上海恒润达生生物科技有限公司 靶向人源化mesothelin的嵌合抗原受体的方法和用途
BR112021006100A2 (pt) * 2018-09-28 2021-07-20 Immpact-Bio Ltd. métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
CA3132458A1 (en) * 2019-03-15 2020-09-24 Rutgers, The State University Of New Jersey Cd147 chimeric antigen receptors and methods of use
SG11202112676VA (en) * 2019-05-16 2021-12-30 Memorial Sloan Kettering Cancer Center Mesothelin cars and uses thereof
MX2022001711A (es) * 2019-08-09 2022-05-10 A2 Biotherapeutics Inc Receptores en la superficie celular que responden a la perdida de heterocigosidad.
CN115052887B (zh) * 2019-12-11 2026-03-31 A2生物治疗公司 基于lilrb1的嵌合抗原受体
IL300500A (en) * 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Preparations and methods for the treatment of mesothelin positive cancer

Also Published As

Publication number Publication date
JP2025503967A (ja) 2025-02-06
WO2023147019A3 (en) 2023-09-14
EP4469559A2 (en) 2024-12-04
AU2023213691A1 (en) 2024-09-05
EP4469559A4 (en) 2025-12-03
IL314114A (en) 2024-09-01
CA3243381A1 (en) 2023-08-03
KR20240155391A (ko) 2024-10-28
US20250269027A1 (en) 2025-08-28
WO2023147019A2 (en) 2023-08-03
CN119403921A (zh) 2025-02-07

Similar Documents

Publication Publication Date Title
MX2023002041A (es) Composiciones y métodos para tratar cánceres positivos para mesotelina.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2022003264A1 (es) Péptidos y sus combinaciones para uso en inmunoterapia contra el cáncer de próstata y otros
CO2021005471A2 (es) Terapia del cáncer con células inmunitarias anti-ptk7
CL2020003461A1 (es) Un derivado del dímero de pirrolobenzodiazepina (pbd) reticulado y sus conjugados
MX2022007678A (es) Compuestos y metodos para la degradacion dirigida del receptor de androgenos.
ECSP18073836A (es) Moléculas de unión a bcma y métodos de uso de las mismas
MX2016012176A (es) Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
MX2018004546A (es) Composiciones y métodos para la inhibicion de antígenos específicos de linaje.
MX2021005395A (es) Terapia del cáncer con células inmunitarias anti-liv1.
AR108468A1 (es) POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
MX2023008779A (es) Adenovirus armado con un activador biespecifico de linfocitos t.
CL2023003965A1 (es) Inhibidores cdk2.
MX2022000726A (es) Anticuerpos inmunomoduladores y metodos de uso de los mismos.
UY36968A (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
CL2023003085A1 (es) Composiciones y métodos para reducir el mhc de clase ii en una célula
MX2023002017A (es) Composiciones y métodos para tratar cánceres positivos para ceacam.
CL2023003089A1 (es) Composiciones y métodos para modificar genéticamente ciita en una célula
CL2023003086A1 (es) Composiciones y métodos para reducir los hla-a en una célula
MX2018000267A (es) Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer.
MX2022005815A (es) Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70.
MX2021009967A (es) Metodos para producir celulas t autologas utiles para tratar cancer y composiciones de las mismas.
MX2024009338A (es) Composiciones y metodos para tratamiento de canceres positivos a mesotelina.
MX2021013368A (es) Celulas t del receptor de antigenos quimericos focalizadas a cd19 especificas del antigeno.
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.